Amlodipine and ARB combination therapy increased the likelihood of achieving blood pressure control by 2.25 times compared to amlodipine monotherapy in patients with primary hypertension.
Meta-Analysis (n=6,401)
Double-blind and single-blind
Randomized controlled trials
Yes
Does first-line combination therapy of amlodipine and an ARB improve blood pressure control compared to amlodipine monotherapy in patients with primary hypertension?
First-line combination therapy with amlodipine and an ARB significantly improves blood pressure control compared to amlodipine monotherapy without increasing the risk of adverse events.
Effect estimate: OR 2.25 (95% CI 1.78-2.83)
Absolute Event Rate: 63.2% vs 47.2%
p-value: p=<0.00001
Background Some clinical guidelines recommend initiating combination antihypertensive therapy as first-line treatment rather than monotherapy. Evidence indicates that a substantial proportion of patients with hypertension require more than one antihypertensive agent to achieve recommended blood pressure targets. However, it remains unclear whether the benefits of initiating combination therapy outweigh the potential risks compared with antihypertensive monotherapy. Objective This systematic review and meta-analysis was conducted to assess the efficacy of blood pressure control and the risk of drug-related adverse events associated with amlodipine monotherapy compared against first-line combination therapy of amlodipine and an angiotensin receptor blocker (ARB) in patients with primary hypertension. Methods A systematic literature search was conducted in PubMed, PubMed Central, and the Cochrane Library up to 15 November 2025, using the following search terms: “amlodipine” AND “angiotensin receptor blocker” AND “primary hypertension” AND “randomized controlled trial.” Only randomized controlled trials comparing amlodipine monotherapy with first-line combination therapy of amlodipine and an ARB, administered for at least 8 weeks, were included. The primary outcomes were blood pressure control and drug-related adverse events. Meta-analysis was performed using Review Manager (RevMan), version 5.4. Results Based on six included studies, the analytical results showed that combination therapy with Calcium Channel Blocker (CCB) and an ARB was associated with 2.25 (odds ratio = 2.25: 95% CI: 1.78–2.83) times odds ratio with statistically significant overall effect ( P 0.00001) and 0.93 (risk ratio = 0.93: 95% CI: 0.82–1.05) times risk ratio with statistically insignificant overall effect ( P = 0.24) compared with CCB (amlodipine 5 mg) monotherapy. Conclusions The results of this study indicate that combination therapy with CCB and an ARB is associated with a 2.25-fold higher likelihood of achieving blood pressure control, with a significant correlation, and a lower risk of drug-related adverse events, without a significant correlation, compared with CCB monotherapy.
Pintaningrum et al. (2026) conducted a meta-analysis in Primary hypertension (n=6,401). Amlodipine and ARB combination therapy vs. Amlodipine monotherapy (5 mg) was evaluated on Blood pressure control (systolic <140 mmHg and/or diastolic <90 mmHg) (OR 2.25, 95% CI 1.78-2.83, p=<0.00001). Amlodipine and ARB combination therapy increased the likelihood of achieving blood pressure control by 2.25 times compared to amlodipine monotherapy in patients with primary hypertension.